Skip to content

Evaluation of Irritation by Two Facial Gels Applied to Opposite Sides of the Face

An Investigator-Blind, Phase 4 Study Assessing the Facial Irritation Potential of Two Acne Treatment Products Using A Split-Face Model

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00919191
Enrollment
26
Registered
2009-06-12
Start date
2009-04-30
Completion date
2009-05-31
Last updated
2012-02-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acne Vulgaris

Keywords

acne, irritation, objective sensory methods

Brief summary

A study to compare the skin irritation potential of two marketed gels for acne treatment, each applied to half of the face of healthy volunteers.

Detailed description

At the Baseline Visit, following satisfaction of entry criteria and screening procedures, all subjects will be applying two products to their faces, each on one side only. The side of the face receiving each product is randomly assigned. One group will use Retin-A MICRO Gel, (tretinoin) 0.04% Pump on the left side of the face and Epiduo Gel (adapalene .1% and benzoyl peroxide 2.5%), on the right side of the face daily for 3 consecutive weeks after washing with study-supplied facial wash. The other group will use the same products, but on opposite sides of the face for three consecutive weeks after washing with the same study-supplied facial wash. Subjects will return to the study center every weekday morning for evaluation and application of both study products. Applications done on the weekends, will be done at home by the subject. At each visit the subject will be scored for cutaneous treatment effects by a blinded evaluator. At baseline and at the end of each week, subjects will be photographed and have chromometer readings.

Interventions

Tretinoin gel 0.04% used once daily in a split-face model

DRUGAdapalene and Benzoyl peroxide

Adapalene .1% and Benzoyl peroxide 2.5%

Sponsors

Bausch Health Americas, Inc.
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
SINGLE (Investigator)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 40 Years
Healthy volunteers
Yes

Inclusion criteria

* Healthy volunteers * Before screening, subjects (or legally authorized representative) must read and sign the IRB approved Informed Consent Form (includes HIPPA and Photo release) * Subjects must have Fitzpatrick Skin Type I, II or III, and judged by the Investigator to have healthy skin * Subject's bilateral facial skin must be clear of any confounding irritation, rashes, acne, rosacea, etc. prior to the study * Subject must be free of systemic retinoids for at least 2 months * Subject must not be using any topical retinoids, systemic antibiotics, nicotinamide or systemic steroids for 1 month prior to study start * All other topical medications to face (e.g., steroids, antimicrobials, salicylic acid and benzoyl peroxide) and cosmetics containing retinols, AHA's and bleaching agents such as hydroquinone are to be discontinued at least 2 weeks prior to study initiation * Subjects will not apply any emollients and cosmetics to the facial area 24 hours prior to study initiation * Subject must not be planning to become pregnant or nursing before entering the study and during the study period. In addition if using birth control pills, subject must be stabilized for at least 2 months. If subject is of child bearing potential, subject must be using approved method of birth control. Approved methods are birth control pills, implants, patches or spermicide with condoms.

Exclusion criteria

* Subjects who are pregnant or nursing * Subjects who have a grade 1 or more for facial erythema * Subjects who exhibit any skin condition (i.e., atopic dermatitis, seborrheic dermatitis, and psoriasis) or disease that may require concurrent therapy or may confound the evaluation of drug safety or efficacy * Subjects who have a history of hypersensitivity to any of the formulation components listed in Appendix 1. * Subjects who have received any experimental drug or used any experimental device 30 days prior to initiation of study therapy * Subjects who have excessive facial hair that may obstruct or hinder the evaluation of any reactions * Subjects who use any known photosensitizing agents * Subjects who presently have skin cancer or actinic keratosis on the face

Design outcomes

Primary

MeasureTime frameDescription
Comparative Assessment of Facial Irritation and Cutaneous Effects.Daily, for 3 weeksExpert Grader Assessment, including cumulative scores for Erythema and Dryness on a scale of 0=none to 8=severe

Secondary

MeasureTime frameDescription
Self Assessment of Burning/Stinging and ItchingDaily, for 3 weeksCumulative scores of Subjects' self assessment of burning/stinging and itching on a score from 0=none to 3=severe

Countries

United States

Participant flow

Participants by arm

ArmCount
Tretinoin and Adapalene Benzoyl Peroxide Facial Gels
One group will use Retin-A MICRO Gel, (tretinoin) 0.04% Pump on the left side of the face and Epiduo Gel (adapalene .1% and benzoyl peroxide 2.5%), on the right side of the face daily for 3 consecutive weeks after washing with study-supplied facial wash. The other group will use the same products, but on opposite sides of the face for three consecutive weeks after washing with the same study-supplied facial wash.
26
Total26

Baseline characteristics

CharacteristicTretinoin and Adapalene Benzoyl Peroxide Facial Gels
Age, Categorical
<=18 years
0 Participants
Age, Categorical
>=65 years
0 Participants
Age, Categorical
Between 18 and 65 years
26 Participants
Age Continuous29.1 years
STANDARD_DEVIATION 5.8
Region of Enrollment
United States
26 participants
Sex: Female, Male
Female
26 Participants
Sex: Female, Male
Male
0 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
— / —
other
Total, other adverse events
0 / 26
serious
Total, serious adverse events
0 / 26

Outcome results

Primary

Comparative Assessment of Facial Irritation and Cutaneous Effects.

Expert Grader Assessment, including cumulative scores for Erythema and Dryness on a scale of 0=none to 8=severe

Time frame: Daily, for 3 weeks

Population: All participants used both gels concurrently, on opposite sides of the face (split-face model)

ArmMeasureGroupValue (MEAN)Dispersion
Tretinoin Facial GelComparative Assessment of Facial Irritation and Cutaneous Effects.Cumulative Erythema1.1 Scores on a ScaleStandard Deviation 1.2
Tretinoin Facial GelComparative Assessment of Facial Irritation and Cutaneous Effects.Cumulative Dryness3.2 Scores on a ScaleStandard Deviation 5.3
Adapalene Benzoyl Peroxide Facial GelComparative Assessment of Facial Irritation and Cutaneous Effects.Cumulative Erythema2.7 Scores on a ScaleStandard Deviation 7.8
Adapalene Benzoyl Peroxide Facial GelComparative Assessment of Facial Irritation and Cutaneous Effects.Cumulative Dryness6.2 Scores on a ScaleStandard Deviation 9.9
Secondary

Self Assessment of Burning/Stinging and Itching

Cumulative scores of Subjects' self assessment of burning/stinging and itching on a score from 0=none to 3=severe

Time frame: Daily, for 3 weeks

ArmMeasureGroupValue (MEAN)Dispersion
Tretinoin Facial GelSelf Assessment of Burning/Stinging and ItchingCumulative Burning/Stinging1.4 Scores on a ScaleStandard Deviation 2.1
Tretinoin Facial GelSelf Assessment of Burning/Stinging and ItchingCumulative Itching0.7 Scores on a ScaleStandard Deviation 0.7
Adapalene Benzoyl Peroxide Facial GelSelf Assessment of Burning/Stinging and ItchingCumulative Burning/Stinging3.7 Scores on a ScaleStandard Deviation 4.8
Adapalene Benzoyl Peroxide Facial GelSelf Assessment of Burning/Stinging and ItchingCumulative Itching1.9 Scores on a ScaleStandard Deviation 3

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026